clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2020-98-7-503-507clinmed-96Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSРоссийские инновации лечения артериальной гипертонии в клинической практике — реальный путь к достижению успехаRussian innovations in the treatment of arterial hypertension in clinical practice — a real way to achieve successhttps://orcid.org/0000-0001-7581-4138БоровковаН. Ю.BorovkovaN. Yu.

Боровкова Наталья Юрьевна — доктор медицинских наук, профессор кафедры госпитальной терапии и общей врачебной практики им. В.Г. Вогралика

603950, Нижний Новгород

Natalia Yu. Borovkova — MD, PhD, DSc, Professor of the Department of hospital therapy and general medical practice named after V.G. Vogralik

603950, Nizhny Novgorod

borovkov-nn@mail.ruФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияVolga Research Medical University, Ministry of Health of RussiaRussian Federation202031122020967503507Copyright © Боровкова Н.Ю., 20202020Боровкова Н.Ю.Borovkova N.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/96

Обзор посвящен знакомству широкого круга интернистов с новой фиксированной комбинацией рамиприла и индапамида (Консилар-Д24), созданной российскими учеными. Это первая оригинальная отечественная разработка для лечения артериальной гипертонии, которая с успехом производится первым российским резидентом особой экономической зоны — фармацевтическим заводом «ВЕРТЕКС» в Санкт-Петербурге. Преимуществом Консилара-Д24 является рациональное сочетание двух препаратов, имеющих не только антигипертензивный и органопротективный эффект, но и большую убедительную базу исследований их влияния на прогноз жизни пациентов с сердечно-сосудистыми заболеваниями: артериальной гипертонией, ишемической болезнью сердца, сердечной недостаточностью.

The review is devoted to introducing a wide range of internists to the new fixed combination of ramipril and indapamide (Concealar-D24), created by Russian scientists. This is the first original domestic development for the treatment of arterial hypertension, which is successfully produced by the first Russian resident of the special economic zone, the pharmaceutical plant «VERTEX» in St. Petersburg. The advantage of Concealar-D24 is a rational combination of two drugs that have not only antihypertensive and organoprotective effects, but also a large convincing base of research on their impact on the prognosis of life in patients with cardiovascular diseases: arterial hypertension, coronary heart disease, heart failure.

артериальная гипертонияиндапамидрамиприлфиксированная комбинацияarterial hypertensionindapamideramiprilfixed combinationReferencesWilliams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J. Hypertens. 2019;37(1):226]. J. Hypertens. 2018;36(10):1953–2041. DOI: 10.1097/HJH.0000000000001940.Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J. Hypertens. 2019;37(1):226]. J. Hypertens. 2018;36(10):1953–2041. DOI: 10.1097/HJH.0000000000001940.Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23. DOI: 10.1016/S0140-6736(05)17741-1.Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23. DOI: 10.1016/S0140-6736(05)17741-1.Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4–11. DOI: 10.15829/1728-8800-2014-6-4-11.4Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V. et al. The prevalence of non-infectious diseases risk factors in russian population in 2012–2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. (in Russian). DOI: 10.15829/1728-8800-2014-6-4-11.4Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;4:4–14. DOI: 10.15829/1728-8800-2014-4-4-14Boytsov S.A., Balanova Y.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4– 14. (in Russian). DOI: 10.15829/1728-8800-2014-4-4-14Gottesman R.F., Albert M.S., Alonso A. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74:1246–1254.Gottesman R.F., Albert M.S., Alonso A. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74:1246–1254.Rovio S.P., Pahkala K., Nevalainen J. et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J. Am. Coll. Cardiol. 2017;69:2279–2289.Rovio S.P., Pahkala K., Nevalainen J. et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J. Am. Coll. Cardiol. 2017;69:2279–2289.Vishram J.K., Borglykke A., Andreasen A.H. et al. MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60:1117– 1123.Vishram J.K., Borglykke A., Andreasen A.H. et al. MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60:1117– 1123.Brown D.W., Giles W.H., Greenlund K.J. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am. J. Hypertens. 2007;20:338–341.Brown D.W., Giles W.H., Greenlund K.J. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am. J. Hypertens. 2007;20:338–341.Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786.Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (in Russian). DOI: 10.15829/1560-4071-2020-3-3786.Lewington S., Clarke R., Qizilbash N. et al. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.Lewington S., Clarke R., Qizilbash N. et al. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/ Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018;(12):131–42.Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Memorandum of experts of the Russian society of cardiology on the recommendations of the European society of cardiology/European society for arterial hypertension for the treatment of arterial hypertension 2018. Russian journal of cardiology. 2018;(12):131–42. (in Russian).Ferrari R. Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc. Med. 2004;9(2):71–89.Ferrari R. Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc. Med. 2004;9(2):71–89.Ceconi C., Francolini G., Olivares A. et al. Angiotensin-converting enzyme (ACE) inhibitors have diff erent selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007;577(1–3):1–6. DOI: 10.1016/j.ejphar.2007.07.061.Ceconi C., Francolini G., Olivares A. et al. Angiotensin-converting enzyme (ACE) inhibitors have diff erent selectivity for bradykinin binding sites of human somatic ACE. Eur. J. Pharmacol. 2007;577(1–3):1–6. DOI: 10.1016/j.ejphar.2007.07.061.Smith W., Ball S.G. Ramipril. Int. J. Clin. Pract. 2000;54:255–60.Smith W., Ball S.G. Ramipril. Int. J. Clin. Pract. 2000;54:255–60.Frampton J.E., Peters D.H. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995;49:440–66. DOI: 10.2165/00003495-199549030-00008Frampton J.E., Peters D.H. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995;49:440–66. DOI: 10.2165/00003495-199549030-00008van Griensven J.M., Schoemaker R.C., Cohen A.F. et al. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur. J. Clin. Pharmacol. 1995;47:513–18. DOI: 10.1007/bf00193704van Griensven J.M., Schoemaker R.C., Cohen A.F. et al. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur. J. Clin. Pharmacol. 1995;47:513–18. DOI: 10.1007/bf00193704Lonn E., Shaikholeslami R., Yi Q. et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J. Am. Coll. Cardiol. 2004;43:2200–06. DOI: 10.1016/j.jacc.2003.10.073Lonn E., Shaikholeslami R., Yi Q. et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J. Am. Coll. Cardiol. 2004;43:2200–06. DOI: 10.1016/j.jacc.2003.10.073Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute MI: the healing and early afterload reducing therapy trial. Circulation. 1997;95:2643–51. DOI: 10.1161/01.cir.95.12.2643Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute MI: the healing and early afterload reducing therapy trial. Circulation. 1997;95:2643–51. DOI: 10.1161/01.cir.95.12.2643The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–28.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–28.Kjoller-Hansen L., Steffensen R., Grande P. The Angiotensin-converting enzyme inhibition post revascularization study (APRES). J. Am. Coll. Cardiol. 2000;35:881–88. DOI: 10.1016/s0735-1097(99)00634-8Kjoller-Hansen L., Steffensen R., Grande P. The Angiotensin-converting enzyme inhibition post revascularization study (APRES). J. Am. Coll. Cardiol. 2000;35:881–88. DOI: 10.1016/s0735-1097(99)00634-8Hollander W., Wilkins R.W. Chlorothiazide: a new type of drug for the treatment of hypertension. BMQ 1957;8:68–75.Hollander W., Wilkins R.W. Chlorothiazide: a new type of drug for the treatment of hypertension. BMQ 1957;8:68–75.Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-tohead comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J. Hypertens. 2015;33:1321–41. DOI: 10.1097/HJH.0000000000000614Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-tohead comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J. Hypertens. 2015;33:1321–41. DOI: 10.1097/HJH.0000000000000614Ames R.P. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am. J. Cardiol. 1996;77(6):12b–6b. DOI: 10.1016/s0002-9149(97)89233-8Ames R.P. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am. J. Cardiol. 1996;77(6):12b–6b. DOI: 10.1016/s0002-9149(97)89233-8Leonetti G., Rappelli A., Salvetti A., Scapellato L. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension. An Italian multicenter study. Am. J. Med. 1988;84(1B):59–64.Leonetti G., Rappelli A., Salvetti A., Scapellato L. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension. An Italian multicenter study. Am. J. Med. 1988;84(1B):59–64.Fuenmayor N.T., Moreira E., de los Rios V. et al. Relations between fasting serum insulin, glucose, and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: shortterm eff ects of antihypertensive drugs. J. Cardiovasc. Pharmacol. 1997;30(4):523–27. DOI: 10.1097/00005344-199710000-00018Fuenmayor N.T., Moreira E., de los Rios V. et al. Relations between fasting serum insulin, glucose, and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: shortterm eff ects of antihypertensive drugs. J. Cardiovasc. Pharmacol. 1997;30(4):523–27. DOI: 10.1097/00005344-199710000-00018Reaven G.M., Clinkingbeard C., Jeppesen J. et al. Comparison of the hemodynamic and metabolic eff ects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am. J. Hypertens. 1995;8(5 Pt 1):461–66. DOI: 10.1016/0895-7061(95)00055-TReaven G.M., Clinkingbeard C., Jeppesen J. et al. Comparison of the hemodynamic and metabolic eff ects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am. J. Hypertens. 1995;8(5 Pt 1):461–66. DOI: 10.1016/0895-7061(95)00055-TBataillard A., Schiavi P., Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin. Pharmacokinet. 1999;37(1):7–12. DOI: 10.2165/00003088-199937001-00002Bataillard A., Schiavi P., Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin. Pharmacokinet. 1999;37(1):7–12. DOI: 10.2165/00003088-199937001-00002Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 2000;18(10):1465–75. DOI: 10.1097/00004872-200018100-00015Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens. 2000;18(10):1465–75. DOI: 10.1097/00004872-200018100-00015Puig J.G., Marre M., Kokot F. et al. Effi cacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am. J. Hypertens. 2007;20(1):90–7. DOI: 10.1016/j.amjhyper.2006.05.018Puig J.G., Marre M., Kokot F. et al. Effi cacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am. J. Hypertens. 2007;20(1):90–7. DOI: 10.1016/j.amjhyper.2006.05.018PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358(9287):1033–41. DOI: 10.1016/S0140-6736(01)06178-5PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358(9287):1033–41. DOI: 10.1016/S0140-6736(01)06178-5Bloch M.J., Basile J.N. Treating hypertension in the oldest of the old reduces total mortality: results of the Hypertension in the Very Elderly Trial (HYVET). J. Clin. Hypertens. (Greenwich). 2008;10(6):501– 3. DOI: 10.1111/j.1751-7176.2008.08056.xBloch M.J., Basile J.N. Treating hypertension in the oldest of the old reduces total mortality: results of the Hypertension in the Very Elderly Trial (HYVET). J. Clin. Hypertens. (Greenwich). 2008;10(6):501– 3. DOI: 10.1111/j.1751-7176.2008.08056.xКонради А.О., Недогода С.В., Недошивин А.О., Ратова Л.Г., Либис Р.А., Арутюнов Г.П., и др. Современная антигипертензивная терапия: возможности уникальной российской фиксированной комбинации рамиприла и индапамида. Российский кардиологический журнал. 2020;25(3):3782. DOI: 10.15829/1560-4071-2020-3-3782Konradi A.O., Nedogoda S.V., Nedoshivin A.O., Ratova L.G., Libis R.A., Arutyunov G.P.et al. Modern Antihypertensive Therapy: possibilities of a Unique Russian fi xed Combination of Ramipril and Indapamide. Russian journal of cardiology. 2020;25(3):3782. (in Russian). DOI: 10.15829/1560-4071-2020-3-3782

The authors declare that there are no conflicts of interest present.